紫杉醇联合顺铂新辅助化疗方案治疗中晚期食管癌98例

目的:了解紫杉醇联合顺铂新辅助化疗方案治疗中晚期食管癌的疗效。方法:选取中晚期食管癌共98例。所有患者术前接受的新辅助化疗方案为:紫杉醇135mg/m2,第1天;顺铂60mg/m2,第1天。每3周为1个周期,共两个周期。观察原发病灶的缓解情况。结果:临床有效率为45.9%(45/98),其中完全缓解率(CR)23.5%(23/98),部分缓解率(PR)22.5%(22/98),疾病稳定(SD)43.9%(43/98),疾病进展(PD)10.2%(10/98),术后病理水平缓解率6.1%(6/98)。结论:紫杉醇联合顺铂新辅助化疗方案治疗中晚期食管癌疗效显著。

A clinical study on the combination of paclitaxel and cisplatin as neoadjuvant chemotherapy in the treatment of advanced esophageal carcinoma

Objective:To evaluate the efficacy of paclitaxel(TAX) plus cisplatin(CDDP) as the neoadjuvant chemotherapy in the treatment of locally advanced esophageal carcinoma(LAEC).Methods:98 cases of patients with LAEC were treated with TP before operation from September 2000 to September 2004.The neoadjuvant chemotherapy regimen is as follows:paclitaxel, 135mg/m~2(day1) plus cisplatin,60mg/ m2(day1) were administered every 3 weeks for 2 cycles .Results were observed in each patient.Results:The clinical efficacy rate was 46%(23.5%CR and 22.5%PR, 43.9%SD and 10.2%PD).Pathological response rate was 6.1%(6/98).Conclusion:The combination of paclitaxel and cisplatin was an effective regimen as neoadjuvant chemotherapy for LAEC.